SLFN11 and ovarian carcinoma: SLFN11 also confers hypersensitivity to PARPis in pre-clinical models [9, 29, 30], and a recent clinical study analyzing the effects of SLFN11 on olaparib sensitivity in patients with ovarian cancer showed that high SLFN11 expression is associated with improved clinical outcomes [31].